Enveric Biosciences, Inc. ENVB 深 沪
已收盘 06-26 16:00:00 美东时间
1.415
+0.135
+10.55%
华盛通- 最 高1.4599
- 今 开1.31
- 成交量 21.34万股
- 最 低 1.2701
- 昨 收 1.28
- 总市值 570.03万
- 52周最高 17.64
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.26
- 委 比 83.18%
- 总股本 402.85万
- 历史最高 2700000.00
- 量 比 1.53
- 振 幅 14.83%
- 历史最低 1.26
- 每 手 1
- 风险率 4.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enveric Biosciences Expands At-The-Market Equity Offering
Enveric Biosciences ( ($ENVB) ) just unveiled an update. On June 9, 2026, Enver...
06-10 06:51
Enveric Biosciences Releases Updated Investor Presentation Materials
An update from Enveric Biosciences ( ($ENVB) ) is now available. Enveric Biosci...
06-09 18:47
Enveric Biosciences Initiates Investigational New Drug-enabling Genotoxicity Studies Of EB-003
Studies are designed to evaluate the potential for the compound to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission
06-02 20:10
Enveric Biosciences shares are trading lower. The company announced preclinical in vitro results showing no photoreactive potential for EB‑003, further derisking its neuropsychiatric program.
Enveric Biosciences shares are trading lower. The company announced preclinical...
05-20 01:34
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
Trump's psychedelic drug order boosts investor interest with promise of faster reviews By Kamal Choudhury and Christy Santhosh May 18 (Reuters) - U.S. President Donald Trump's executive order to accelerate psychedelic drug development has raised hopes among companies developing the drugs that it cou
05-18 18:00
Enveric Biosciences Q1 EPS $(1.08) Up From $(14.64) YoY
Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(1.08) per share. This is a 92.62 percent increase over losses of $(14.64) per share from the same period last year.
05-15 20:16
Enveric Biosciences Highlights Results for EB-003 In PTSD Preclinical Model; Says Previously Reported Results Support Continued Development Of EB-003 For PTSD, Other Neuropsychiatric Condition
Enveric Biosciences today highlighted preclinical data for its lead candidate, EB-003, a dual 5-HT2A and 5-HT1B modulator, in which a single dose of EB-003 significantly reduced context-induced freezing behavior one hour
05-05 20:00
Enveric Biosciences Corrects Reverse Stock Split Proxy Disclosure
The latest announcement is out from Enveric Biosciences ( ($ENVB) ). On April 1...
05-01 05:31
What's Going On With Enveric Biosciences Stock On Friday?
The FDA issues priority vouchers and clears early trials for ibogaine derivatives for using psychedelics for therapy and mental health.
04-25 02:13
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 63.0% to $0...
04-25 01:05
